Proficio Capital Partners just added 2,230 shares of AbbVie, giving its portfolio a pharma-flavored boost worth $1.18 million ...

Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA ...

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Caterpillar Inc. (NYSE:CAT). In a filing ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Shares of AbbVie were recently trading for $212 apiece, and the company's total annual dividend amount (paid out over four ...

AbbVie’s stock dipped 0.29% to close at $213.85, a minor move compared to the S&P 500's steeper 1.07% drop. Despite this ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...